Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $22.